1 / 29

Top Tips in Evidence-Based Care for HFrEF

Explore evidence-based care tips for typical HFrEF patients, delving into key therapies outlined in the 2016 ESC Guidelines. Learn the benefits of MRA and ARNI integration, successful treatment principles, and drug titration strategies. Discover the impact of ARNI on reducing CV events and HF hospitalizations, with insights from the PARADIGM-HF trial. Uncover SGLT2 inhibitors' role in managing diabetes and HFrEF, including ongoing trials and implications in altered patient scenarios like tachycardia in HFrEF. Gain valuable knowledge on managing HF in the inpatient setting, anticoagulation in AF, and safety considerations for ARNI use in HFrEF patients. This comprehensive guide provides expert advice and key points for optimizing care in HFrEF.

wilmat
Download Presentation

Top Tips in Evidence-Based Care for HFrEF

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Top Tips in Evidence-Based Care for HFrEF

  2. Typical Patient With HFrEF

  3. Key Therapies in HFrEF: How Do They Work?

  4. 2016 ESC HF Guidelines: Next...Add an MRA and ARNI

  5. Principles for Successful Treatment for HF

  6. Starting and Titrating Drug Therapies in HFrEF

  7. ESC 2016 Guidelines: Classifications of HF

  8. CHARM: Candesartan Reduced CV Death + Time to First HF Hospitalization in HFrEF and HFmrEF Categories

  9. Benefit of ARNI in HFrEF: Primary Composite Endpoint -- CV Death and First HF Hospitalization

  10. Additional Key Points: PARADIGM-HF

  11. PARADIGM-HF: Benefit of ARNI in HFrEF to Reduce Time to First Hospitalization for HF Was Seen Very Early

  12. Managing Diabetes in the Presence of HFrEF

  13. SGLT2 Inhibitors: Use in Diabetes and HF

  14. Ongoing Trials With SGLT2 Inhibitors in Patients With Diabetes and HF

  15. Questions to Ponder and Points of Clarification: SGLT2 Inhibitors in HF

  16. Altered Patient Scenario: Tachycardia in HFrEF

  17. SHIFT Trial: Increased Risk of CV Death and HF Hospitalization With Increased Heart Rate in SR in HF

  18. AF and HF

  19. Heart Rate as a Predictor of Outcome in HF

  20. Anticoagulation and AF in HF

  21. Management of HF in the Inpatient Setting

  22. PIONEER HF: Safety of ARNI -- Including ACE Inhibitor and ARB-Naive Patients With HFrEF

  23. PIONEER HF: Exploratory Clinical Endpoints

  24. Clarification of Terms -- What Do We Mean?

  25. Conclusions

  26. Abbreviations

  27. Abbreviations (cont)

  28. Abbreviations (cont)

More Related